"Triazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D014230
|
| MeSH Number(s) |
D03.383.129.799
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Triazoles".
Below are MeSH descriptors whose meaning is more specific than "Triazoles".
This graph shows the total number of publications written about "Triazoles" by people in this website by year, and whether "Triazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 2 | 3 |
| 1997 | 2 | 3 | 5 |
| 1998 | 4 | 0 | 4 |
| 1999 | 3 | 0 | 3 |
| 2000 | 4 | 2 | 6 |
| 2001 | 6 | 3 | 9 |
| 2002 | 12 | 1 | 13 |
| 2003 | 14 | 12 | 26 |
| 2004 | 12 | 5 | 17 |
| 2005 | 15 | 3 | 18 |
| 2006 | 14 | 3 | 17 |
| 2007 | 4 | 3 | 7 |
| 2008 | 9 | 3 | 12 |
| 2009 | 9 | 3 | 12 |
| 2010 | 10 | 7 | 17 |
| 2011 | 11 | 5 | 16 |
| 2012 | 13 | 7 | 20 |
| 2013 | 11 | 8 | 19 |
| 2014 | 7 | 10 | 17 |
| 2015 | 17 | 8 | 25 |
| 2016 | 9 | 8 | 17 |
| 2017 | 14 | 8 | 22 |
| 2018 | 6 | 8 | 14 |
| 2019 | 8 | 2 | 10 |
| 2020 | 7 | 3 | 10 |
| 2021 | 6 | 7 | 13 |
| 2022 | 1 | 3 | 4 |
| 2024 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Triazoles" by people in Profiles.
-
Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues. Eur J Med Chem. 2024 Dec 05; 279:116904.
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
-
Rizatriptan benzoate-loaded dissolving microneedle patch for management of acute migraine therapy. J Biomater Appl. 2024 04; 38(9):989-999.
-
Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2024 Jun 01; 130(11):1964-1971.
-
Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes. J Antimicrob Chemother. 2024 02 01; 79(2):297-306.
-
Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies. Clin Infect Dis. 2022 10 29; 75(9):1503-1510.
-
Triazole Priming as an Adaptive Response and Gateway to Resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2022 08 16; 66(8):e0045822.
-
Synthesis and Immunological Study of N-Glycan-Bacteriophage Q? Conjugates Reveal Dominant Antibody Responses to the Conserved Chitobiose Core. Bioconjug Chem. 2022 07 20; 33(7):1350-1362.
-
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. 2022 08 01; 40(22):2479-2490.